Ernexa Therapeutics Inc. (NASDAQ:ERNA) Short Interest Update

Posted by on Sep 2nd, 2026

Ernexa Therapeutics Inc. (NASDAQ:ERNA – Get Free Report) saw a significant increase in short interest during the month of August. As of August 14th, there was short interest totaling 24,656 shares, an increase of 68.8% from the July 30th total of 14,605 shares. Based on an average daily volume of 47,948 shares, the days-to-cover ratio is currently 0.5 days. Approximately 1.5% of the shares of the company are short sold.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Brookline Capital Markets began coverage on Ernexa Therapeutics in a research note on Thursday, May 7th. They issued a “buy” rating and a $30.00 target price on the stock. Zacks Research raised Ernexa Therapeutics to a “hold” rating in a report on Monday, May 11th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ernexa Therapeutics in a research note on Friday, July 17th. Finally, Wall Street Zen downgraded shares of Ernexa Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Ernexa Therapeutics presently has an average rating of “Hold” and a consensus target price of $30.00.

Check Out Our Latest Research Report on ERNA

Ernexa Therapeutics Price Performance

NASDAQ ERNA opened at $4.35 on Wednesday. The stock’s 50 day simple moving average is $5.07 and its 200-day simple moving average is $6.46. Ernexa Therapeutics has a 1-year low of $3.18 and a 1-year high of $71.50. The company has a market cap of $7.09 million, a PE ratio of -0.30 and a beta of 2.61.

Ernexa Therapeutics (NASDAQ:ERNA – Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($3.40) EPS for the quarter, missing analysts’ consensus estimates of ($3.30) by ($0.10). On average, equities research analysts anticipate that Ernexa Therapeutics will post -18.02 EPS for the current fiscal year.

Hedge Funds Weigh In On Ernexa Therapeutics

An institutional investor recently bought a new stake in Ernexa Therapeutics stock. Susquehanna International Group LLP purchased a new stake in Ernexa Therapeutics Inc. (NASDAQ:ERNA – Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned about 0.39% of Ernexa Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 70.55% of the company’s stock.

About Ernexa Therapeutics

(Get Free Report)

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.

Read More

Receive News & Ratings for Ernexa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ernexa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.